Originally posted on August 10, 2023 @ 11:04 MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the second quarter of 2023. MoonLake continues to make significant progress with the clinical development of sonelokimab…
No responses yet